Bio-Rad Laboratories (BIO) Non Operating Investment Income (2018 - 2026)

Bio-Rad Laboratories (BIO) has reported Non Operating Investment Income for 9 consecutive years, with -$738.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Non Operating Investment Income fell 2421.38% year-over-year to -$738.2 million; the TTM figure through Mar 2026 stood at -$867.3 million (up 47.39% YoY), while the FY2020 annual figure was $4.5 billion, up 121.36% from the prior year.
• Non Operating Investment Income retreated to -$738.2 million in Q1 2026 per BIO's latest filing, from -$495.3 million in the prior quarter.
• Across five years, Non Operating Investment Income topped out at $792.9 million in Q3 2024 and bottomed at -$4.5 billion in Q1 2022.
• Historically, Non Operating Investment Income has averaged -$792.0 million across 5 years, with a median of -$289.0 million in 2022.
• Annual changes were most pronounced in 2024 — Non Operating Investment Income soared 2509.13% — and 2026, when it slumped 2421.38%.
• Bio-Rad Laboratories' Non Operating Investment Income stood at -$289.0 million in 2022, then soared by 112.6% to $36.4 million in 2023, then surged by 2076.8% to $792.9 million in 2024, then slumped by 162.47% to -$495.3 million in 2025, then slumped by 49.04% to -$738.2 million in 2026.
• Business Quant data shows BIO's Non Operating Investment Income at -$738.2 million in Q1 2026, -$495.3 million in Q3 2025, and $334.4 million in Q2 2025.